Discussion on supply side reform and improvement of quality assurance system in pharmaceutical industry

Source: on March 3, 2016, in the first year of the 13th five year plan, the supply side structural reform proposed by the central government is becoming the starting point of the new normal for the development of various industries, including the pharmaceutical industry On the occasion of the national two sessions in 2016, Yang Wenlong, member of the National Committee of the Chinese people's Political Consultative Conference, recently submitted a proposal to the conference, suggesting that the state should study and formulate a strategic development plan for the pharmaceutical industry, accelerate the transformation and upgrading of "pharmaceutical Internet +", and help the supply side structural reform In an interview, industry insiders such as China Pharmaceutical (12.300,0.00,0.00%) Enterprise Management Association said that the supply side structural reform of the pharmaceutical industry, in addition to "touching the net", also needs to focus on many aspects "Medicine Internet +" may have three benefits for everyone to know Medicine is a basic project related to national economy and people's livelihood, directly related to people's health and quality of life With the deepening of China's aging and the implementation of the "comprehensive two child" policy, the rigid demand for medical services is further highlighted Since the "Internet +" was put forward, the "medical Internet +" has rapidly resonated in the whole industry, and the mutual penetration of traditional medicine industry and Internet industry is also increasing However, for the role of "medical Internet +", Yang Wenlong summed up three "advantages", that is, to deepen and improve the medical reform, to promote the transformation and upgrading of the pharmaceutical industry, to enhance the productivity level of the pharmaceutical industry, and to comprehensively implement and realize the supply side reform In view of the obstacles and problems in the transformation and upgrading of "medical Internet +", Yang Wenlong also put forward a complete set of solutions in the proposal He proposed that the policy orientation of "medical Internet +" industrial upgrading should be made clear first, that is, the research proposition of "Internet +" strategic development plan of medical industry during the 13th five year plan "should be set up at the national level, and" medical Internet + "should be made clear In terms of strategic mission and development direction of supply side reform, domestic industry development and medical reform, through top-level design, we will improve the policy, boundary, resources and supervision of "medical Internet +", and lead the "medical Internet +" to conform to identity, legal compliance and scientific development On the basis of the planning, we should promote the research and promulgation of relevant detailed rules, strengthen industrial support and supervision, and enhance the access threshold At the same time, we should strengthen the support and supervision of the "pharmaceutical Internet +" industrial transformation by strengthening industry norms and guidance Yu Mingde, President of China Pharmaceutical Enterprise Management Association, said in an interview that in addition to the Internet +, the supply side reform of the pharmaceutical industry involves at least three other tasks "What should the Internet +, or the pharmaceutical industry +? We should pay attention to the objective fact that the whole world is using Internet technology to reduce costs Therefore, the Internet + in the pharmaceutical industry can start from the perspective of circulation For example, the medical o2o mode aimed at connecting online and offline can achieve the effect of reducing cost and increasing efficiency through the combination of online and offline In addition, once the online trading of prescription drugs is gradually opened in the future, the field of pharmaceutical circulation will change dramatically As we all know, at present, only 10% of drugs are allowed to be traded online, and more than 80% of prescription drugs have not been allowed to be sold online " That's what Yu Mingde said In Mingde's view, a fundamental problem for the supply side structural reform of the pharmaceutical industry is the growing demand of the common people (43.120, - 0.29, - 0.67%) The existing industries are not fully satisfied Some fields still depend on foreign supply The main tasks of transformation and upgrading have not been completed Yu also said that the first of the remaining three tasks of the supply side reform of the pharmaceutical industry is to follow the path of internationalization and keep abreast of the world's highest standards "At present, the production capacity of the domestic pharmaceutical industry is very large, and many products are also needed in other parts of the world, but they cannot go out If the reliability of the quality assurance system is aligned with the highest level in the world, and with Europe, the United States and Japan, then the problem of overcapacity in some domestic pharmaceutical industries will be solved accordingly " Yu said further Secondly, it is necessary to develop bio medicine In his opinion, among the eight sub industries of the pharmaceutical industry, biomedicine is the one with the smallest gap with the world In terms of gene medicine, therapeutic vaccine and monoclonal antibody research, China has a certain foundation, but it still needs to keep up with the international pace and innovate In addition, we should vigorously develop large health industries The big health industry should be the health products and health services that run through people's life At present, China has done a lot in products In the fields of medical service and health service, there is still room for improvement in many places For example, sub-health management, door-to-door care, chronic disease management, home-based care for the elderly and other aspects need further development The supply side reform of the medical industry is also needed Obviously, "medical industry innovation" and "vigorously develop medical services" have been generally considered as the direction of the supply side reform of the medical industry However, in view of the current tightening of medical resources, especially doctors' resources, some private medical professionals said in an interview that the supply side reform of the pharmaceutical industry also involves the medical industry Tu Zhiliang, chairman and President of gushengtang chain group of traditional Chinese medicine, believed that the construction of Medical Association should be accelerated The so-called "medical consortia" refers to a medical consortia cooperative medical organization composed of a three-level first-class hospital, a second-class hospital in a certain area, community health services and other institutions The mode is mainly to strengthen the service capacity construction of primary health institutions, encourage the development of rehabilitation and nursing institutions, build a diagnosis and treatment mode of graded medical treatment, rapid and slow treatment, two-way referral, serve the grassroots masses, form a synergy, and achieve the purpose of facilitating the masses to seek medical treatment In addition, drop the superior medical resources of the top three hospitals to the grass-roots level, through two-way referral, let the patients enjoy the substantial preferential policy of 10% increase in reimbursement ratio, and then form the Trinity Mode of "the first diagnosis is in the community, the critical illness is transferred to the hospital, and the recovery is back to the community" It will also be able to alleviate the problem of doctors' resource shortage in large hospitals to a certain extent "Now we are talking about supply side reform Specifically, the key to the medical industry is to change the ability of resource allocation so that good doctors are" long "at the grassroots level." Tu Zhiliang said so It is understood that at present, private medical services, including gushengtang and Pingan haodoctor, are trying to introduce online HMO (health maintenance organization managed medical service organization) mode from abroad HMO's assessment of doctors is no longer the prescription and examination, but the quality and value of medical services The core consideration of doctors is to make patients less sick In addition, HMO managers can also provide doctors with motivation for health services through doctor training and performance setting Rdpac: the supply side transformation and upgrading reform needs to run through the whole pharmaceutical industry chain Zhuo Yongqing, President of the pharmaceutical research and development industry committee (rdpac) of China Association of foreign funded enterprises, said in an exclusive interview that the launch of supply side reform in China has far-reaching impact on the domestic pharmaceutical industry However, to really do a good job in this reform, it is not enough to do a good job in Internet + medicine and other fields It is not difficult to find that the transformation and upgrading of China's pharmaceutical industry first involves three aspects First, raw materials, auxiliary materials, packaging materials and other production factors should be included in the scope of transformation and upgrading, which involves many fields such as how to improve the quality of generic drugs Secondly, relevant laws and regulations should be followed up Thirdly, the upgrading of the pharmaceutical industry also needs to achieve linkage between the upstream and downstream, that is, from research and development, to production materials, to preparation technology, to production, to circulation and distribution, as well as payment Only in this way can China's pharmaceutical industry be truly integrated into the global chain.